share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4:持股變動聲明-高管 Gibson Christopher
美股SEC公告 ·  08/27 16:15

Moomoo AI 已提取核心訊息

Recursion Pharmaceuticals CEO Christopher Gibson acquired 5,000 shares of the company's Class A Common Stock on 08/27/2024. The transaction was executed at a price of $2.48 per share, indicating a total investment of $12,400. Following this purchase, Gibson's direct holdings in the company increased to 747,656 shares. The transaction, which is currently in progress, was reported as an exercise or conversion of derivative security.
Recursion Pharmaceuticals CEO Christopher Gibson acquired 5,000 shares of the company's Class A Common Stock on 08/27/2024. The transaction was executed at a price of $2.48 per share, indicating a total investment of $12,400. Following this purchase, Gibson's direct holdings in the company increased to 747,656 shares. The transaction, which is currently in progress, was reported as an exercise or conversion of derivative security.
Recursion Pharmaceuticals首席執行官Christopher Gibson於2024年08月27日購買了公司的5,000股A類普通股。交易價格爲每股2.48美元,總投資金額爲12,400美元。在此次購買後,Gibson在該公司的直接持股增至747,656股。目前正在進行的交易被報告爲衍生證券的行權或轉換。
Recursion Pharmaceuticals首席執行官Christopher Gibson於2024年08月27日購買了公司的5,000股A類普通股。交易價格爲每股2.48美元,總投資金額爲12,400美元。在此次購買後,Gibson在該公司的直接持股增至747,656股。目前正在進行的交易被報告爲衍生證券的行權或轉換。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息